ADPT insider transaction filings
Adaptive Biotechnologies Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen ADPT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 29 legs across 17 filings by 9 insiders — 2,194,486 shares, $51,003,842 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: sale of 318,799 shares @ $25.08 ($7,995,479) by ROBINS CHAD M, filed 2026-08-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ROBINS HARLAN S — Chief Scientific Officer | 2 | — | 4 legs · 878,640 sh · $19,281,558 | 2 |
| ROBINS CHAD M — CEO and Chairman, Director | 1 | — | 4 legs · 600,000 sh · $14,882,166 | 4 |
| LO FRANCIS — Chief People Officer | 3 | — | 6 legs · 317,010 sh · $7,784,850 | 30 |
| BENZENO SHARON — Chief Commercial Ofc Imm Med | 1 | — | 2 legs · 165,802 sh · $3,503,510 | 10 |
| NEUPERT PETER M — Director | 1 | — | 3 legs · 124,690 sh · $3,135,850 | 2 |
| GRIFFIN MICHELLE RENEE — Director | 1 | — | 1 leg · 52,084 sh · $1,051,055 | 2 |
| HERSHBERG ROBERT — Director | 1 | — | 2 legs · 30,664 sh · $748,208 | 2 |
| BOBULSKY SUSAN — Chief Commercial Officer, MRD | 6 | — | 6 legs · 15,981 sh · $366,655 | — |
| OWEN KATEY EINTERZ — Director | 2 | — | 1 leg · 9,615 sh · $249,990 | 1 |
Recent Form 4 filings — Adaptive Biotechnologies Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | LO FRANCIS — Chief People Officer | Option exercise (M): 53,091 @ $12.14 · Option exercise (M): 13,398 @ $8.46 · Option exercise (M): 15,629 @ $3.99 · Option exercise (M): 23,442 @ $8.12 · Sale (S): 107,537 @ $28.02 · Sale (S): 7,869 @ $28.57 · +4 more | EDGAR |
| 2026-09-17 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 1,195 @ $27 | EDGAR |
| 2026-09-02 | 4 | OWEN KATEY EINTERZ — Director | Gift (G): 12,539 | EDGAR |
| 2026-08-28 | 4 | OWEN KATEY EINTERZ — Director | Sale (S): 9,615 @ $26 | EDGAR |
| 2026-08-20 | 4 | HERSHBERG ROBERT — Director | Option exercise (M): 15,000 @ $6.32 · Sale (S): 15,000 @ $24.39 · Sale (S): 15,664 @ $24.41 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | ROBINS CHAD M — CEO and Chairman, Director | Option exercise (M): 321,324 @ $6.55 · Sale (S): 318,799 @ $25.08 · Sale (S): 2,525 @ $25.57 · Option exercise (M): 278,676 @ $6.55 · Sale (S): 278,472 @ $24.48 · Sale (S): 204 @ $25.14 · +2 more | EDGAR |
| 2026-08-19 | 4 | NEUPERT PETER M — Director | Option exercise (M): 15,000 @ $6.32 · Sale (S): 15,000 @ $25.23 · Sale (S): 40,000 @ $25.10 · Sale (S): 69,690 @ $25.16 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 3,000 @ $25 | EDGAR |
| 2026-08-03 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 1,299 @ $24 | EDGAR |
| 2026-07-23 | 4 | ROBINS HARLAN S — Chief Scientific Officer | Option exercise (M): 284,800 @ $6.55 · Sale (S): 278,698 @ $21.72 · Sale (S): 213,702 @ $22.12 · Option exercise (M): 284,800 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 5,000 @ $23 | EDGAR |
| 2026-07-17 | 4 | LO FRANCIS — Chief People Officer | Option exercise (M): 59,374 @ $7.80 · Option exercise (M): 23,677 @ $12.14 · Option exercise (M): 22,711 @ $8.46 · Sale (S): 105,762 @ $22.59 · Option exercise (M): 59,374 (derivative) @ $0 · Option exercise (M): 23,677 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-07 | 4 | ROBINS HARLAN S — Chief Scientific Officer | Sale (S): 239,351 @ $21.74 · Sale (S): 146,889 @ $22.45 | EDGAR |
| 2026-07-06 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 487 @ $22 | EDGAR |
| 2026-07-06 | 4 | LO FRANCIS — Chief People Officer | Option exercise (M): 3,500 @ $7.80 · Option exercise (M): 3,300 @ $12.14 · Option exercise (M): 12,206 @ $8.46 · Option exercise (M): 4,688 @ $3.99 · Option exercise (M): 14,064 @ $8.12 · Sale (S): 8,743 @ $22.18 · +13 more | EDGAR |
| 2026-06-30 | 4 | BENZENO SHARON — Chief Commercial Ofc Imm Med | Option exercise (M): 11,034 @ $12.14 · Sale (S): 11,034 @ $21 · Option exercise (M): 1,837 @ $12.14 · Option exercise (M): 24,944 @ $8.46 · Option exercise (M): 24,944 @ $3.99 · Option exercise (M): 51,570 @ $8.12 · +6 more | EDGAR |
| 2026-06-29 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 5,000 @ $20.50 | EDGAR |
| 2026-06-29 | 4 | GRIFFIN MICHELLE RENEE — Director | Option exercise (M): 52,084 @ $7.80 · Sale (S): 52,084 @ $20.18 · Option exercise (M): 52,084 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | ROBINS HARLAN S — Chief Scientific Officer | Sale (S): 100,000 @ $17.37 · Sale (S): 6,160 @ $18.01 | EDGAR |
| 2026-06-15 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 5,000 @ $19 | EDGAR |
| 2026-06-08 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 11,000 @ $18 | EDGAR |
| 2026-06-08 | 4 | LO FRANCIS — Chief People Officer | Option exercise (M): 5,792 @ $12.14 · Option exercise (M): 2,009 @ $8.46 · Option exercise (M): 2,344 @ $3.99 · Option exercise (M): 9,376 @ $8.12 · Sale (S): 39,741 @ $17.49 · Option exercise (M): 5,792 (derivative) @ $0 · +3 more | EDGAR |
| 2026-05-20 | 4 | PISKEL KYLE — Chief Financial Officer | Sale (S): 3,115 @ $13.04 | EDGAR |
| 2026-04-29 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,707 @ $8.46 · Sale (S): 19,037 @ $14.23 · Option exercise (M): 14,707 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.13 · Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $13.74 · Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.02 · +3 more | EDGAR |
| 2026-04-21 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.57 · Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.55 · Option exercise (M): 14,722 @ $8.46 · Option exercise (M): 11,881 @ $12.14 · +5 more | EDGAR |
| 2026-04-16 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.56 · Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.61 · Option exercise (M): 14,722 @ $8.46 · Sale (S): 19,060 @ $14.18 · +3 more | EDGAR |
| 2026-04-13 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $7.27 · Sale (S): 16,960 @ $13.79 · Sale (S): 2,100 @ $14.44 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 18,660 @ $12.75 · Sale (S): 400 @ $13.48 · +8 more | EDGAR |
| 2026-04-10 | 4 | ROBINS HARLAN S — Chief Scientific Officer | Sale (S): 10,000 @ $14.85 | EDGAR |
| 2026-04-10 | 4 | LO FRANCIS — Chief People Officer | Option exercise (M): 2,344 @ $3.99 · Sale (S): 22,564 @ $15.07 · Option exercise (M): 2,344 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $14.33 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $13.56 · Option exercise (M): 14,722 @ $7.27 · Option exercise (M): 11,881 @ $12.14 · +6 more | EDGAR |
| 2026-04-08 | 4 | ROBINS CHAD M — CEO and Chairman, Director | Sale (S): 83,332 @ $14.41 · Sale (S): 37,263 @ $15.19 | EDGAR |
| 2026-04-02 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $14.45 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $14.60 · Option exercise (M): 14,722 (derivative) @ $0 · Option exercise (M): 14,722 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $7.27 · Sale (S): 2,738 @ $12.49 · Sale (S): 16,322 @ $13.48 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $12.63 · Option exercise (M): 14,722 @ $7.27 · +4 more | EDGAR |
| 2026-03-26 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $13.70 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $14.27 · Option exercise (M): 14,722 @ $7.27 · Sale (S): 19,060 @ $14.12 · +3 more | EDGAR |
| 2026-03-23 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $6.55 · Sale (S): 19,060 @ $13.18 · Option exercise (M): 3,939 @ $6.55 · Option exercise (M): 10,783 @ $7.27 · Sale (S): 19,060 @ $13.37 · Option exercise (M): 14,722 @ $7.27 · +5 more | EDGAR |
| 2026-03-18 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $6.55 · Sale (S): 19,060 @ $13.41 · Option exercise (M): 14,722 @ $6.55 · Sale (S): 19,060 @ $13.40 · Option exercise (M): 14,722 @ $6.55 · Sale (S): 19,060 @ $13.18 · +3 more | EDGAR |
| 2026-03-13 | 4 | BOBULSKY SUSAN — Chief Commercial Officer, MRD | Sale (S): 41,338 @ $13.17 | EDGAR |
| 2026-03-13 | 4 | BENZENO SHARON — Chief Commercial Ofc Imm Med | Sale (S): 63,103 @ $13.17 | EDGAR |
| 2026-03-13 | 4 | ROBINS HARLAN S — Chief Scientific Officer | Sale (S): 140,666 @ $13.17 · Sale (S): 329,600 @ $13.17 | EDGAR |
| 2026-03-13 | 4 | RUBINSTEIN JULIE — President and COO | Sale (S): 122,523 @ $13.17 · Option exercise (M): 14,722 @ $6.55 · Sale (S): 19,060 @ $14.08 · Option exercise (M): 14,722 @ $6.55 · Sale (S): 13,660 @ $12.63 · Sale (S): 5,400 @ $13.43 · +5 more | EDGAR |
| 2026-03-13 | 4 | PISKEL KYLE — Chief Financial Officer | Sale (S): 18,672 @ $13.17 | EDGAR |
| 2026-03-13 | 4 | LO FRANCIS — Chief People Officer | Sale (S): 30,593 @ $14.08 | EDGAR |
| 2026-03-13 | 4 | ROBINS CHAD M — CEO and Chairman, Director | Sale (S): 140,567 @ $13.17 · Sale (S): 329,600 @ $13.17 | EDGAR |
| 2026-03-13 | 4 | GRIFFIN MICHELLE RENEE — Director | Sale (S): 15,394 @ $13.91 | EDGAR |
| 2026-03-10 | 4 | RUBINSTEIN JULIE — President and COO | Option exercise (M): 14,722 @ $6.55 · Option exercise (M): 11,881 @ $12.14 · Sale (S): 30,941 @ $15.14 · Option exercise (M): 14,722 @ $6.55 · Option exercise (M): 11,881 @ $12.14 · Sale (S): 30,941 @ $14.79 · +9 more | EDGAR |
| 2026-03-09 | 4 | LO FRANCIS — Chief People Officer | Sale (S): 38,074 @ $15.09 | EDGAR |
| 2026-03-06 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 15,625 @ $0 | EDGAR |
| 2026-03-06 | 4 | NEUPERT PETER M — Director | Grant/award (A): 15,625 @ $0 | EDGAR |
| 2026-03-06 | 4 | GRIFFIN MICHELLE RENEE — Director | Grant/award (A): 15,625 @ $0 | EDGAR |
Recent 8-K events — Adaptive Biotechnologies Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-18 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADPT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →